This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

TD Cowen Remains a Buy on Dexcom (DXCM)

Tipranks - Tipranks - Wed Jun 10, 5:32PM CDT

In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Dexcom, with a price target of $95.00.

Introducing TipRanks MCP for Agents

Jennings covers the Healthcare sector, focusing on stocks such as Dexcom, Boston Scientific, and Edwards Lifesciences. According to TipRanks, Jennings has an average return of 1.3% and a 45.20% success rate on recommended stocks.

Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $81.74.

See the top stocks recommended by analysts >>

Based on Dexcom’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.19 billion and a net profit of $199.5 million. In comparison, last year the company earned a revenue of $1.04 billion and had a net profit of $105.4 million

Read More on DXCM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).